音声ブラウザ対応ページへコンテンツエリアへ  ログイン  
 
トップ ＞ 研究者情報 

利用者サービス

業績検索業績所属別一覧業績施設別一覧研究者検索

入力規則・ヘルプ

!!はじめての方へ!!
＊＊＊＊＊＊＊＊
◆研究者情報
・研究者情報入力方法
　・所属一覧
・研究者検索方法
・研究者ダウンロード方法

◆業績
・業績入力方法
　・業績項目 解説
・外部データ取り込み方法
　・TSVデータ作成方法
・業績検索方法
・業績ダウンロード方法

＊＊＊＊＊＊＊＊
・Q&A 
 

昭和大学研究者情報・業績集

・研究者情報登録・業績公開申請の流れ

・説明会
　・昭和大学研究者情報・業績集
　・説明会動画  

 

リンク

　

 昭和大学


 昭和大学図書館

 昭和大学学術業績リポジトリ
(全文公表)



 

お問い合わせ

昭和大学図書館　業績集係

e-mail：　
achieve[at]lib.showa-u.ac.jp
(2019.07.04～変更)

tel：03-3784-8042
 

研究者情報

鶴谷　純司
TSURUTANI Junji
大学講座なし先端がん治療研究所
旗の台校舎
教授
 of 2       表示件数  件
Ｎｏ. ▽ 刊行年月 ▼ 業績項目 ▽ 著者 タイトル・書名 ▽ 雑誌名/学会・シンポジウム名 ▽ 巻 ▽ 号 ▽ 開始ページ ▽
1045212 2021-11 会議発表(論文・口頭) 山岡　利光
岸野　康成
楠本　壮二郎
安藤　浩一
大森　亨
相良　博典
鶴谷　純司
 EGFR遺伝子変異を有する肺腺癌細胞PC-9における第３世代EGFR-TKI, オシメルチニブの獲得耐性機序の検討
第62回日本肺癌学会学術集会
1042309 2021-10 会議発表(論文・口頭) 佐々木　晶子
垂野　香苗
鶴谷　純司
和泉　麻里子
木内　祐二
中村　清吾
 ハンドセラピー施術と冷却法の併用によるCIPNのしびれ改善方法
第59回日本癌治療学会学術集会
1044612 2021-10 会議発表(論文・口頭) 山岡　利光
岸野　康成
楠本　壮二郎
安藤　浩一
大森　亨
相良　博典
鶴谷　純司
 肺腺癌細胞PC-9における第3世代EGFR-TKI,オシメルチニブの獲得耐性機序の検討
第80回⽇本癌学会学術総会
1044024 2021-08 学術雑誌論文(学内) 鶴谷　純司
 乳がんに対する薬物療法の最前線 昭和学士会雑誌
 81 3 162
1046197 2021-07 会議発表(論文・口頭) 有泉　裕嗣
吉村　清
堀池　篤
平澤　優弥
石黒　智之
大熊　遼太朗
久保田　祐太郎
濵田　和幸
和田　聡
鶴谷　純司
角田　卓也
 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例
第25回日本がん免疫学会総会
1040986 2021-02 学術雑誌論文(学外) MATSUNAGA Yuki
YAMAOKA Toshimitsu
OHBA Motoi
MIURA Sakiko
MASUDA Hiroko
SANGAI Takafumi
TAKIMOTO Masafumi
NAKAMURA Seigo
TSURUTANI Junji
 Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. Antibodies (Basel)
 10 1 6
1041386 2020-12 学術雑誌論文(学外) LIU Lei
MATSUNAGA Yuki
TSURUTANI Junji
AKASHI-TANAKA Sadako
MASUDA Hiroko
IDE Yoshimi
HASHIMOTO Rikako
INUZUKA Mayuko
WATANABE Chie
TARUNO Kanae
SAWADA Terumasa
OKUYAMA Hiromi
ATA Arisa
KUWAYAMA Takashi
NAKAYAMA Sayuka
TONOUCHI Yumi
NAKAMURA Seigo
 BRCAness as a prognostic indicator in patients with early breast cancer. Sci Rep
 10 1 21173
1040534 2020-10 学術雑誌論文(学外) YAMAOKA Toshimitsu
TSURUTANI Junji
SAGARA Hironori
OHMORI Tohru
 HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. Transl Lung Cancer Res
 9 5 2178
1039481 2020-09 会議発表(論文・口頭) 山岡　利光
大森　亨
安藤　浩一
楠本　壮二郎
本間　哲也
岸野　康成
眞鍋　亮
相良　博典
鶴谷　純司
 EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討
第60回日本呼吸器学会学術講演会
1037691 2020-05 学術雑誌論文(学外) LI Bob T.
MICHELINI Flavia
MISALE Sandra
COCCO Emiliano
BALDINO Laura
CAI Yanyan
SHIFMAN Sophie
TU Hai-Yan
MYERS Mackenzie L.
XU Chongrui
MATTAR Marissa
KHODOS Inna
LITTLE Megan
QERIQI Besnik
WEITSMAN Gregory
WILHEM Clare J.
LALANI Alshad S.
DIALA Irmina
FREEDMAN Rachel A.
LIN Nancy U.
SOLIT David B.
BERGER Michael F.
BARBER Paul R.
NG Tony
OFFIN Michael
ISBELL James M.
JONES David R.
Yu Helena A.
THYPARAMBIL Sheeno
LIAO Wei-Li
BHALKIKAR Anuja
CECCHI Fabiola
HYMAN David M.
LEWIS Jason S.
BUONOCORE Darren J.
HO Alan L.
MAKKER Vicky
REIS-FILHO Jorge S.
RAZAVI Pedram
ARCILA Maria E.
KRIS Mark G.
POIRIER John T.
SHEN Ronglai
TSURUTANI Junji
ULANER Gary A.
DE STANCHINA Elisa
ROSEN Neal
RUDIN Charles M.
SCALTRITI Maurizio
 HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov
10 5 674
1037692 2020-05 学術雑誌論文(学外) TSURUTANI Junji
IWATA Hiroji
KROP Ian
JÄNNE Pasi A
DOI Toshihiko
TAKAHASHI Shunji
PARK Haeseong
REDFERN Charles
TAMURA Kenji
WISE-DRAPER Trisha M
SAITO Kaku
SUGIHARA Masahiro
SINGH Jasmeet
JIKOH Takahiro
GALLANT Gilles
LI Bob T
 Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov
 10 5 688
1037693 2020-05 学術雑誌論文(学外) SHIMOI Tatsunori
NAGAI Shigenori E
YOSHINAMI Tetsuhiro
TAKAHASHI Masato
ARIOKA Hitoshi
ISHIHARA Mikiya
KIKAWA Yuichiro
KOIZUMI Kei
KONDO Naoto
SAGARA Yasuaki
TAKADA Masahiro
TAKANO Toshimi
TSURUTANI Junji
NAITO Yoichi
NAKAMURA Rikiya
HATTORI Masaya
HARA Fimikata
HAYASHI Naoki
MIZUNO Toshiro
MIYASHITA Minoru
YAMASHITA Nami
YAMANAKA Takashi
SAJI Shigehira
IWATA Hiroji
TOYAMA Tatsuya
 The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer
 27 3 322
1036821 2020-05 学術雑誌論文(学外) 佐々木　晶子
池田　明子
角田　ゆう子
澤田　晃暢
鶴谷　純司
辰尾　秋斗
木内　祐二
中村　清吾
 化学療法誘発性末梢神経障害を有する乳がん患者に対するハンドセラピー施術後の改善効果の検討 癌と化学療法
 47 5 783
1037690 2020-02 学術雑誌論文(学外) MODI Shanu
PARK Haeseong
MURTHY Rashmi K
IWATA Hiroji
TAMURA Kenji
TSURUTANI Junji
MORENO-ASPITIA Alvaro
DOI Toshihiko
SAGARA Yasuaki
REDFERN Charles
KROP Ian E
LEE Caleb
FUJISAKI Yoshihiko
SUGIHARA Masahiro
ZHANG Lin
SHAHIDI Javad
TAKAHASHIi Shunji
 Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol
JCO1902318
1037035 2020-02 学術雑誌論文(学外) MODI Shanu
SAURA Cristina
YAMASHITA Toshinari
PARK Yeon Hee
KIM Sung-Bae
TAMURA Kenji
ANDRE Fabrice
IWATA Hiroji
ITO Yoshinori
TSURUTANI Junji
SOHN Joohyuk
DENDULURI Neelima
PERRIN Christophe
AOGI Kenjiro
TOKUNAGA Eriko
IM Seock-Ah
LEE Keun Seok
HURVITZ Sara A
CORTES Javier
LEE Caleb
CHEN Shuquan
ZHANG Lin
SHAHIDI Javad
YVER Antoine
KROP Ian
DESTINY-Breast01 Investigators
 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med
 382 7 610
1037689 2020-01 学術雑誌論文(学外) INOUE Kenichi
TAKAHASHI Masato
MUKAI Hirofumi
YAMANAKA Takashi
EGAWA Chiyomi
SAKATA Yukinori
IKEZAWA Hiroki
MATSUOKA Toshiyuki
TSURUTANI Junji
 Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs
 e
1037688 2020-01 学術雑誌論文(学外) OHKUMA Ryotaro
YADA Erica
ISHIKAWA Shumpei
KOMURA Daisuke
ISHIZAKI Hidenobu
TAMADA Koji
KUBOTA Yutaro
HAMADA Kazuyuki
ISHIDA Hiroo
HIRASAWA Yuya
ARIIZUMI Hirotsugu
SATOH Etsuko
SHIDA Midori
WATANABE Makoto
ONOUE Rie
ANDO Kiyohiro
TSURUTANI Junji
YOSHIMURA Kiyoshi
YOKOBORI Takehiko
SASADA Tetsuro
AOKI Takeshi
MURAKAMI Masahiko
NOROSE Tomoko
OHIKE Nobuyuki
TAKIMOTO Masafumi
IZUMIZAKI Masahiko
KOBAYASHI Shinichi
TSUNODA Takuya
WADA Satoshi
 High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. PLoS One
 15 1 e0226707
1036401 2020-01 学術雑誌論文(学外) HARATANI Koji
YONESAKA Kimio
TAKAMURA Shiki
MAENISHI Osamu
KATO Ryoji
TAKEGAWA Naoki
KAWAKAMI Hisato
TANAKA Kaoru
HAYASHI Hidetoshi
TAKEDA Masayuki
MAEDA Naoyuki
KAGARI Takashi
HIROTANI Kenji
TSURUTANI Junji
NISHIO Kazuto
DOI Katsumi
MIYAZAWA Masaaki
NAKAGAWA Kazuhiko
 U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest
 130 1 374
1036731 2019-12 学術雑誌論文(学外) TAMURA Kenji
IMAMURA Chiyo K.
TAKANO Toshimi
SAJI Shigehira
YAMANAKA Takeharu
YONEMORI Kan
TAKAHASHI Masato
TSURUTANI Junji
NISHIMURA Reiki
SATO Kazuhiko
KITANI Akira
UENO Naoto T.
MUSHIRODA Taisei
KUBO Michiaki
FUJIWARA Yasuhiro
TANIGAWARA Yusuke
 CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. J Clin Oncol
 JCO1901412
1036510 2019-12 学術雑誌論文(学外) YOSHIOKA Hiroshige
SHIMOKAWA Mototsugu
SETO Takashi
MORITA Satoshi
YATABE Yasushi
OKAMOTO Isamu
TSURUTANI Junji
SATOUCHI Miyako
HIRASHIMA Tomonori
ATAGI Shinji
SHIBATA Kazuhiko
SAITO Hiroshi
TOYOOKA Shinichi
YAMAMOTO Nobuyuki
NAKAGAWA Kazuhiko
MITSUDOMI Tetsuya
 Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer. Ann Oncol
 30 12 1978
1036509 2019-12 学術雑誌論文(学外) TAKEGAWA Naoki
TSURUTANI Junji
KAWAKAMI Hisato
YONESAKA Kimio
KATO Ryoji
HARATANI Koji
HAYASHI Hidetoshi
TAKEDA Masayuki
NONAGASE Yoshikane
MAENISHI Osamu
NAKAGAWA Kazuhiko
 [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer
 145 12 3414
1037694 2019-12 会議発表(論文・口頭) OZAKI Yukinori
MUKOHARA Toru
TSURUTANI Junji
TAKAHASHI Masato
MATSUMOTO Koji
FUTAMURA Manabu
MASUDA Norikazu
KITANO Shigehisa
YOSHIMURA Kenichi
MINAMI Hironobu
 A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER 2-negative metastatic breast cancer: WJOG 9917 B NEWBEAT trial
San Antonio Breast Cancer Symposium
1037699 2019-12 会議発表(論文・口頭) YOSHINAMI Tetsuhiro
NAKAYAMA Takahiro
IKEDA Masahiko
MIZUTANI Makiko
YAMAGUCHI Miki
KOMOIKE Yoshifumi
TAKASHIMA Tsutomu
YOSHIDOME Katsuhide
TSURUTANI Junji
IWAMOTO Mitsuhiko
FUJISAWA Fumie
YASOJIMA Hiroyuki
YAMAMURA Jun
MORISHIMA Hirotaka
AKI Fuminori
YAMADA Tomomi
MORITA Satoshi
MASUDA Norikazu
 Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR 1214)
San Antonio Breast Cancer Symposium
1037696 2019-12 会議発表(論文・口頭) KATO Hiroaki
HARA Fumikata
KITADA Masahiro
TAKAHASHI Masato
KIKAWA Yuichiro
SAKATA Eiko
NAITO Yoichi
HASEGAWA Yoshie
SAITO Tsuyoshi
IWASA Tsutomu
TSURUTANI Junji
TAIRA Naruto
TAKASHIMA Tsutomu
KASHIWABARA Kosuke
AIHARA Tomohiko
MUKAI Hirofumi
 Patient-reported outcomes in a randomized, optimal dose finding, phase II study of triweekly nab-paclitaxel in patients with metastatic breast cancer (the ABROAD study)
San Antonio Breast Cancer Symposium
1037698 2019-12 会議発表(論文・口頭) MASUDA Jun
TSURUTANI Junji
MASUDA Norikazu
FUTAMURA Manabu
MATSUMOTO Koji
AOGI Kenjiro
TAKAHASHI Masato
IWATA Hiroji
IWASA Tsutomu
MUKOHARA Toru
YOSHIMURA Kenichi
UENO Takayuki
TAKANO Toshimi
 Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG 11418 B, NEWFLAME trial)
San Antonio Breast Cancer Symposium
1037697 2019-12 会議発表(論文・口頭) MASUDA Hiroko
IWASA Tsutomu
MUKOHARA Toru
TOKUNAGA Shinya
MATSUMOTO Koji
NIIKURA Naoki
SAGARA Yasuaki
MIYOSHI Yasuo
SHIMOMURA Akihiko
TAKAHASHI Masato
NAGASHIMA Takeshi
DOI Mihoko
FUTAMURA Manabu
YOSHIMURA Kenichi
TAKANO Toshimi
TSURUTANI Junji
 Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER 2-negative advanced breast cancer (MERMAID) WJOG 11318 B
San Antonio Breast Cancer Symposium
1037695 2019-12 会議発表(論文・口頭) KROP Ian E
SAURA Cristina
YAMASHITA Toshinari
PARK Yeon Hee
KIM Sung-Bae
TAMURA Kenji
ANDRÉ Fabrice
IWATA Hiroji
ITO Yoshinori
TSURUTANI Junji
SOHN Joohyuk
DENDULURI Neelima
PERRIN Christophe
AOGI Kenjiro
TOKUNAGA Eriko
IM Seock-Ah
LEE Keun Seok
HURVITZ Sara
CORTES Javier
LEE Caleb
CHEN Shuquan
ZHANG Lin
SHAHIDI Javad
YVER Antoine
MODI Shanu
 [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER 2-positive metastatic breast cancer previously treated with T-DM 1: A phase 2, multicenter, open-label study （DESTINY-Breast 01
San Antonio Breast Cancer Symposium
1037031 2019-12 その他 鶴谷　純司
 HER2陰性進行再発乳癌に対する治療戦略
第17回日本乳癌学会近畿地方会
1037032 2019-10 学術雑誌論文(学外) IWASA Tsutomu
TSURUTANI Junji
WATANABE Satomi
KATO Ryoji
MIZUNO Yutaka
KOJIMA Yasuyuki
TAKASHIMA Tsutomu
MATSUNAMI Nobuki
MORIMOTO Takashi
YAMAMURA Jun
OHTANI Shoichiro
TANABE Yuko
YOSHINAMI Tetsuhiro
TAKANO Toshimi
KOMOIKE Yoshifumi
NAKAGAWA Kazuhiko
 Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. BMC Cancer
19 1 962
1036981 2019-09 学術雑誌論文(学外) ANDO Kiyohiro
HAMADA Kazuyuki
WATANABE Makoto
OHKUMA Ryotaro
SHIDA Midori
ONOUE Rie
KUBOTA Yutaro
MATSUI Hiroto
ISHIGURO Tomoyuki
HIRASAWA Yuya
ARIIZUMI Hirotsugu
TSURUTANI Junji
YOSHIMURA Kiyoshi
TSUNODA Takuya
KOBAYASHI Shinichi
WADA Satoshi
 Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors Anticancer Res
 39 9 5195
 of 2       表示件数  件

Powered by NetCommons2 The NetCommons Project